<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353040</url>
  </required_header>
  <id_info>
    <org_study_id>6003-us-101</org_study_id>
    <secondary_id>W9113M-10-C-0056</secondary_id>
    <nct_id>NCT01353040</nct_id>
  </id_info>
  <brief_title>Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6003 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Sarepta Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and pharmacology of single
      administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg
      virus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Marburg hemorrhagic fever is a rare human disease caused by the Marburg virus, a filamentous,
      single-stranded, negative-sense RNA virus. In general, the mortality rate associated with
      Marburg virus outbreaks has ranged from 23% to 88%, with the highest death rates seen in more
      recent epidemics. No vaccine or effective therapy is available for Marburg hemorrhagic fever.
      AVI-6003 is an experimental combination of 2 phosphorodiamidate morpholino antisense
      oligomers with positive charges on selected subunits (PMOplus™). These oligomers specifically
      target viral messenger RNA encoding 2 Marburg virus proteins thought to be important in viral
      replication and host immune suppression. The present study is designed to characterize the
      safety, tolerability and pharmacokinetics of escalating single-administration doses of
      AVI-6003 in healthy human subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects experiencing adverse events</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma drug concentration</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine drug concentration</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Marburg Hemorrhagic Fever</condition>
  <arm_group>
    <arm_group_label>AVI-6003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVI-6003</intervention_name>
    <description>Single intravenous administration</description>
    <arm_group_label>AVI-6003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single intravenous administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female and between the ages of 18 and 50 years in good general health

          -  Volunteers must be willing to use barrier methods of contraception or be of
             non-childbearing potential

          -  Volunteers must be willing to undergo a urine screen for drugs of abuse

        Exclusion Criteria:

          -  Pregnancy or breastfeeding.

          -  Any clinically relevant abnormalities in physical examinations, vital signs, ECG,
             clinical chemistry, hematology or urinalysis

          -  Positive test for human immunodeficiency virus, hepatitis B or hepatitis C or known
             history of HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Heald, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Apinya B Vutikullird, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Coast Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Marburg Virus Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

